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Clinical aspects of 11q23 abnormalities in de novo 
childhood acute myeloid leukemia (AML) are 
described. 
Clinics and pathology 
Disease 
Childhood acute myeloid leukemia and 11q23/MLL 
rearrangement 
Phenotype/cell stem origin 
Leukemic cells with 11q23 abnormalities typically 
disrupt the MLL gene; they frequently have a 
myelomonoblastic or monoblastic morphology (FAB 
M4, M5) with accompanying myeloblastic 
immunophenotype of moderate CD45, low SSC, 
CD13+, CD33+, CD34+, CD117+, HL-DR+ and 
monoblastic immunophenotype of bright positive 
CD45, low SSC, CD11b+, CD11c+, CD13+, CD14+, 
CD33+, CD64+, CD4+, CD56+, HLA-DR+. 
Additional cytogenetic lesions are present in 
approximately 50% of patients with an 11q23/MLL 
rearrangement, with trisomy 8 being the most frequent 
(18%). (See Table 1). 
Etiology 
There is strong molecular evidence that 11q23 
abnormalities in pediatric leukemia occur in utero. The 
MLL gene has an important role in normal 
hematopoietic growth and differentiation. 
Abnormalities in this region can occur very early in 
hematopoietic stem cell development.  
In utero exposure to natural or synthetic substances that 
inhibit topoisomerase II (e.g., genistein, catechins, 
flavonoids) may result in acute leukemia.  
It has been suggested that rearrangement of the MLL
gene leads to the inhibition of apoptosis and 
leukemogenesis.  
Acute leukemias of myeloid (AML) and lymphoid 
(ALL) lineage have 11q23/MLL rearrangements but 
show a different predilection for translocation partne s, 
which are thought to be responsible in part for 
development of the phenotype of each type of 
leukemia.  
The brief latency of infant acute leukemias involving 
11q23/MLL rearrangements suggests that the MLL 
fusions need some additional cooperating mutations t  
cause leukemia.  
Recent array comparative genomic hybridization 
(aCGH) and high-throughput genomic studies have 
confirmed these findings. 
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Table 1. Occurrence of different MLL rearrangements according to the French American British (FAB) morphology type in an 
international retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML. * Patients with a clearly indicated sub-
band were classified heir respective categories; other patients for whom data on subband or translocation partner were insufficient were 
classified as noted. Data obtained from an international retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML 
(Balgobind et al., Blood 2009). 
Table 2. Occurrence of different MLL rearrangements by age at diagnosis in an international retrospective study of 756 
pediatric patients with 11q23/MLL rearranged AML. * Percentage within the indicated age group. ¶ Patients with a clearly indicated 
sub-band were classified heir respective categories; other patients for whom data on subband or translocation partner were insufficient 
were classified as noted. Data obtained from an international retrospective study of 756 pediatric patients with 11q23/MLL rearranged 
AML (Balgobind et al., Blood 2009).  
Table 3. Occurrence of different MLL rearrangements by clinical parameters in an international retrospective study of 756 
pediatric patients with 11q23/MLL rearranged AML. * Percentage within the 11q23 abnormality group. ¶ Patients with a clearly 
indicated sub-band were classified heir respective categories; other patients for whom data on subband or translocation partner were 
insufficient were classified as noted. Data obtained from an international retrospective study of 756 pediatric patients with 11q23/MLL 
rearranged AML (Balgobind et al., Blood 2009). 
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Epidemiology 
Depending on the method of detection, the overall 
incidence of 11q23 abnormalities among children with 
AML ranges from 15% to 25%.  
In children younger than 2 years, the peak incidence of 
11q23/MLL gene rearrangements is 50%-60%. By 
contrast, the incidence of 11q23 abnormalities in adults 
with AML is approximately 5%, and these 
abnormalities are rarely seen in patients older than 60 
years. Also, patients with second leukemias, especially 
those administered prior epipodophyllotoxin II 
treatment, have a high incidence of 11q23 aberrations, 
but these are not dealt with in detail here. An estimated 
5%-10% of MLL rearrangements in AML are subtle or 
cryptic and need to be detected by fluorescence in situ 
hybridization (FISH) using the MLL probe, 
preferentially in a sequential G-banded and FISH 
metaphase to identify the partner chromosome. 
Most of the following information was obtained from a 
large international collaborative 
retrospective study consisting of 756 pediatric patients 
with 11q23 abnormalities and AML in which the 
overall 5-year event free survival (EFS) rate was 44%. 
(See Table 2). 
Clinics 
Children with 11q23/MLL rearranged AML often 
present with high white blood cell counts (WBC), 
central nervous system (CNS) involvement and 
organomegaly. (See Table 3). 
Treatment 
In most pediatric AML protocols, patients with 
11q23/MLL rearrangements are treated according to 
intermediate-risk stratification.  
Stem cell transplantation is not generally advised in 
first complete remission.  
A recent study, however, showed significant benefit of 
matched sibling donor stem cell transplantation for 
11q23-rearranged pediatric AML patients in first 
complete remission in the AML-BFM 98 protocol. 
 
Table 4. Outcomes of patients by univariate analysis of different MLL rearrangements and as per clinical and laboratory 
parameters, from an international retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML. Abbreviations: 
pEFS, probability of event free survival; pCIR, probability of cumulative incidence of relapse; pOS, probability of overall survival; SE, 
standard error; WBC, white blood cell count. * P-values of indicated abnormality as compared to 11q23/MLL-rearranged pediatric AML 
patients with other additional cytogenetic abnormalities. ¶ Patients with a clearly indicated sub-band were classified heir respective 
categories; other patients for whom data on subband or translocation partner were insufficient were classified as noted. Data obtained 
from an international retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML (Balgobind et al., Blood 2009). 
 






Atlas Genet Cytogenet Oncol Haematol. 2012; 16(8)  577 
 
Table 5. Hazard ratios from multivariate analysis of different MLL rearrangements and according to additional cytogenetic 
aberrations, from an international retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML. Abbreviations: 
EFS, event free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; P, P-value; ACAs, additional cytogenetic 
aberrations. * P<0.05; † P<0.01. ¶ Patients with a clearly indicated sub-band were classified heir respective categories; other patients for 
whom data on subband or translocation partner were insufficient were classified as noted. Data obtained from an international 
retrospective study of 756 pediatric patients with 11q23/MLL rearranged AML (Balgobind et al., Blood 2009). 
 
Prognosis 
The prognostic significance of 11q23 abnormalities in 
children with AML is unclear, but it appears to depend 
on the partner gene involved and additional 
chromosomal aberrations. Most of the work presented 
here is from an international collaborative retrospective 
study consisting of 756 pediatric patients with 11q23 
abnormalities and AML in which the overall 5-year 
EFS rate was 44%. The outcome of the subgroups 
varied greatly; for example, patients with a 
t(1;11)(q21;q23) had an excellent outcome (5-year 
EFS, 92%) whereas those with a t(6;11)(q27;q23) had 
the worst outcome (5-year EFS, 11%). Subgroups 
t(10;11)(p12;q23), t(4;11)(q21;q23), and 
t(10;11)(p11.2;q23) had a 5-year EFS of 31%, 29%, 
and 17%, respectively. The prognosis of the most 
commonly occurring partner t(9;11) is controversial 
and will be described later. In this retrospective study, 
patients younger than 10 years had a more favorable 
prognosis than those 10 years or older (EFS of 46% and 
34%, respectively) (P=0.006). 
The presence of specific additional cytogenetic 
aberrations was significantly correlated with outcome.  
Patients with trisomy 19 and structural additional 
cytogenetic aberrations had a 5-year EFS of 17% and 
32%, respectively, whereas patients with the most 
frequent specific additional aberration trisomy 8 had a 




- The t(9;11)(p22;q23) is the most frequent 11q23/MLL 
abnormality in pediatric AML, occurring in 
approximately 50% of patients. 
- The fusion gene resulting from this translocation 
involves MLL and AF9 (MLLT3). 
- Additional cytogenetic aberrations have been detect d 
by conventional karyotyping in approximately 47% of 
patients with t(9;11)(p22;q23). The most frequently 
recurring additional aberration is trisomy 8 (~24%). 
- There is no consensus on the outcome of patients with 
t(9;11). A 5-year EFS of 50% and a 5-year OS of 63% 
were reported in an international retrospective study.  
However, the Nordic countries (NOPHO) and St. Jude 
Children's Research Hospital (St. Jude), Memphis, TN, 
USA, have reported that patients with t(9;11)(p22;q3) 
had better prognosis than patients with other 
translocation partners, with a 7-year EFS of 86% in the 
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NOPHO-AML93 trial and a 5-year EFS of 65% in the 
4 consecutive St. Jude trials (1980 to 1997). 
- In some protocols, treatment of t(9;11)(p22;q23) is 
done according to low-risk stratification, but this 
approach is controversial. 
t(10;11)(p12;q23) 
- The t(10;11)(p12;q23) is the second most frequent 
11q23/MLL abnormality in pediatric AML, accounting 
for approximately 13% of all cases of 11q23/MLL 
rearranged pediatric AML.  
However, this percentage is underestimated, because in 
many instances the generation of the fusion gene is 
cryptic or complex (see below). It is difficult to 
accurately establish the breakpoints of 10p in many 
translocations involving 10p and 11q23. 
- The fusion gene resulting from this translocation 
involves MLL and AF10 (MLLT10). 
- To generate an MLL-AF10 fusion, the translocation 
of chromosome 10 and chromosome 11 has to include 
at least one inversion. Most t(10;11)(p12;q23) cases ar  
identified by conventional karyotyping, but structural 
aberrations can be very complex. These aberrations 
include insertions of 11q material onto the 10p armnd 
vice versa, some of which are also cryptic. In some 
instances, FISH using the subtelomeric probes for 10p 
and 11q can clarify the nature of the abnormality. RT-
PCR is also a very useful method to detect the MLL-
AF10 fusion transcript. 
- In approximately 50% of the t(10;11)(p12;q23) cases, 
additional cytogenetic aberrations have been detected 
by conventional karyotyping. The most frequently 
recurring additional aberration is trisomy 8 (~7%); 
diverse structural additional aberrations have been 
detected (36%) and can affect other chromosomes. 
- A 5-year EFS of 31% and a 5-year OS of 45% were 
reported in a large international retrospective study. 
t(10;11)(p11.2;q23) 
- The t(10;11)(p11.2;q23) is a rare 11q23/MLL 
abnormality mainly found in young children with 
AML. However, in the large retrospective study, 3 of 
12 (25%) patients were older than 2 years. 
- The fusion gene resulting from this translocation 
involves MLL and ABI1. 
- In approximately 58% of t(10;11)(p11.2;q23) cases, 
additional cytogenetic aberrations have been detected 
by conventional karyotyping, all cases displaying at 
least one additional structural aberration. 
- A 5-year EFS of 17% and a 5-year OS of 27% were 
reported in a large international retrospective study. 
t(6;11)(q27;q23) 
- The t(6;11)(q27;q23) occurs in approximately 5% of 
all pediatric patients with 11q23/MLL rearranged 
AML. However, this incidence is underestimated as the 
DNA exchanged in this translocation is very subtle and 
may go undetected or be misclassified as a 
del(11)(q23). 
- The fusion gene resulting from this translocation 
involves MLL and AF6 (MLLT4). RT-PCR is also a 
very useful method to identify the MLL-AF6 fusion 
transcript. 
- In approximately 46% of t(6;11)(q27;q23) cases, 
additional cytogenetic aberrations have been detected 
by conventional karyotyping. The most frequent 
recurring additional aberrations are trisomy 8 and 
trisomy 21 (~17% each) and additional structural 
aberrations (~26%). 
- A 5-year EFS of 11% and a 5-year OS of 22% have 
been reported in a large international retrospectiv 
study; t(6;11)(q27;q23) thus represents the subgroup 
with the worst outcome in pediatric 11q23/MLL 
rearranged AML, but the reason for the very poor 
survival rate is unknown. 
t(11;19)(q23;p13) 
- Translocations of chromosome 11q23 with 
chromosome 19p13 occur in approximately 12% of 
pediatric patients with 11q23/MLL rearranged AML. 
Two common translocation partners are present on 
19p13: ELL on 19p13.1 and ENL (MLLT1) on 
19p13.3. In approximately 33% of pediatric AML 
cases, resolution of the karyotype can be insufficient to 
define the sub-band with certainty, and for this 
publication these patients are grouped as 
t(11;19)(q23;p13). 
- A 5-year EFS for patients with a t(11;19)(q23;p13), 
t(11;19)(q23;p13.1), and t(11;19)(q23;p13.3) of 49%, 
46% and 46% respectively, and a 5-year OS of 49%, 
61% and 47%, respectively, have been reported in a 
large international retrospective study. 
t(1;11)(q21;q23) 
- The t(1;11)(q21;q23) occurs in approximately 3% of 
all pediatric patients with 11q23/MLL rearranged 
AML. 
- The fusion gene resulting from this translocation 
involves MLL and AF1q (MLLT11). 
- In approximately 25% of t(1;11)(q21;q23) cases, 
additional cytogenetic aberrations have been detected 
by conventional karyotyping, the most frequent being 
trisomy 6 (13%). 
- A 5-year EFS of 92% and a 5-year OS of 100% have 
been reported in a large international retrospectiv 
study; t(1;11)(q21;q23) thus represents the subgroup 
with the best outcome in pediatric 11q23/MLL 
rearranged AML. 
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Figure 1. Survival curves of different MLL rearrangements, from an international retrospective study of 756 pediatric patients with 
11q23/MLL rearranged AML (Balgobind et al., Blood 2009). 
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Cytogenetics molecular 
Approximately 5% to 10% of cases of AML and an 
MLL gene rearrangement are not detectable by 
conventional cytogenetic methods. Currently, 
commercially available dual-color MLL break-apart 
probes are available that allow FISH evaluation of 
rearrangement in the interphase nuclei and 
identification of the partner/derivative chromosome on 
metaphase chromosomes. In rare instances, segments of 
the MLL probe may be deleted when generating the 
rearrangement; thus FISH may also detect a concurrent 
deletion of 3'MLL and rarely of 5'MLL. 
As mentioned throughout, molecular cytogenetic 
methods have shown that the frequency of MLL gene 
rearrangements exceeds that of 11q23 translocations 
detected by conventional cytogenetic method alone. In 
AML cases in which aberrations affect the 11q23 band, 
a complementary FISH study should be done to 
determine whether a rearrangement of MLL is present, 
as in rare cases an 11q23 translocation may involve 
genes other than MLL. In AML patients with normal 
karyotypes or without an identified type II aberration 
[such as t(8;21), t(15;17) or inv(16)], FISH might 
identify a cryptic MLL rearrangement. Because the 
translocation partners for 11q23 are numerous and 
markedly heterogeneous, additional molecular methods 
may be needed to further assess the partner genes for 
MLL. RT-PCR is suitable to evaluate the most 
frequently observed MLL fusion transcripts, and, if 
positive, can also be useful for following the status of 
the patient's minimal residual disease. In other cases, 
long-distance inverse PCR on genomic DNA can aid 
the finding of uncommon or novel translocation 
partners. 
MLL-partial tandem duplication is a separate entity that 
can only be identified by PCR or other techniques, and
is not discussed here. 
Genetic lesions also occur frequently in 11q23/MLL 
rearranged pediatric AML. In approximately 43% of 
cases, a mutation in one of the RAS-pathway coding 
genes, FLT3 or KIT, has been identified. 
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